Anti-IFNAR Recombinant Antibody (TAB-722)

Customer Review

There are currently no Customer reviews or questions for TAB-722. Click the button above to contact us or submit your feedback about this product.

Laura Scott
18.Oct,23

Ideal for IFNAR Research

The Anti-IFNAR Therapeutic Antibody (anifrolumab) has been excellent for our IFNAR studies. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

David Young
05.Dec,22

Reliable in Multiple Assays

We incorporated this antibody into our Western blot and immunoassays, and it has been a great asset. The specificity for IFNAR is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.

Megan Martinez
09.Jul,21

Consistent High-Quality Results

This antibody has proven to be consistent and high-quality in our various assays. The reproducible results and strong affinity for IFNAR have significantly improved our experiments, making it a crucial part of our research toolkit. The consistent performance has greatly enhanced our data quality.

Q&As

1. Is the anti-Human IFNAR therapeutic antibody Anifrolumab suitable for use in Western blotting?

   A: Yes, the anti-Human IFNAR therapeutic antibody Anifrolumab (TAB-722) is suitable for use in Western blotting. It provides specific binding to IFNAR, allowing for reliable detection in Western blot assays.

2. What are the storage recommendations for the anti-Human IFNAR therapeutic antibody Anifrolumab?

   A: The recommended storage condition for the anti-Human IFNAR therapeutic antibody Anifrolumab (TAB-722) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-Human IFNAR therapeutic antibody Anifrolumab be used in immunoprecipitation assays?

   A: Yes, the anti-Human IFNAR therapeutic antibody Anifrolumab (TAB-722) can be used in immunoprecipitation assays. It provides specific binding to IFNAR, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-Human IFNAR therapeutic antibody Anifrolumab effective in ELISA applications?

   A: Yes, the anti-Human IFNAR therapeutic antibody Anifrolumab (TAB-722) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of IFNAR.

5. What is the optimal dilution for using the anti-Human IFNAR therapeutic antibody Anifrolumab in immunofluorescence?

   A: The optimal dilution for using the anti-Human IFNAR therapeutic antibody Anifrolumab (TAB-722) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Bender, Andrew T., et al. "TLR7 and TLR8 differentially activate the IRF and NF-κB pathways in specific cell types to promote inflammation." Immunohorizons 4.2 (2020): 93-107. https://doi.org/10.4049/immunohorizons.2000002
   This study investigates how TLR7 and TLR8 differentially activate the IRF and NF-κB pathways in specific cell types to promote inflammation. TLR7 and TLR8 are endosomal receptors that recognize single-stranded RNA (ssRNA) and play critical roles in antiviral defense and the pathogenesis of autoimmune diseases such as lupus. The research uses cell sorting, gene expression analysis, and intracellular cytokine staining to characterize the effects of TLR7 and TLR8 activation in various human immune cells. The study found that TLR7 primarily activates the IRF pathway leading to type I IFN production, while TLR8 predominantly activates the NF-κB pathway, resulting in the production of inflammatory cytokines. These findings enhance the understanding of the distinct roles TLR7 and TLR8 play in immune responses and their contributions to autoimmune diseases.
   Creative Biolabs provided the anti-IFNAR antibody anifrolumab (Cat#: TAB-722) used in this study. Anifrolumab was crucial in experiments designed to block type I IFN activity, allowing researchers to differentiate between gene expression changes directly induced by TLR7/8 activation and those mediated by secondary IFN responses. The antibody was pivotal in demonstrating that inhibiting IFN activity can prevent secondary IFN-induced gene expression while not affecting NF-κB-regulated genes directly induced by TLR7/8 activation. This contribution was essential for elucidating the distinct pathways and effects mediated by TLR7 and TLR8 activation in various cell types.
2. Zheng, Jian, et al. "Severe acute respiratory syndrome coronavirus 2-induced immune activation and death of monocyte-derived human macrophages and dendritic cells." The Journal of infectious diseases 223.5 (2021): 785-795. https://doi.org/10.1093/infdis/jiaa753
   This study examines the infection and immune response of human monocyte-derived macrophages (MDMs) and dendritic cells (MDDCs) by SARS-CoV-2. The research found that although SARS-CoV-2 infects these cells abortively, it still induces the production of multiple proinflammatory cytokines and chemokines, such as IFN-α, IFN-β, TNF, IL-1β, IL-6, IL-8, IL-10, and CXCL10. This infection triggers a type I IFN-mediated cell death, contributing to the inflammatory response observed in COVID-19. The study also demonstrated that infection is dependent on the ACE2 receptor and that the presence of convalescent plasma can block this infection without enhancing macrophage cell death, suggesting the non-involvement of antibody-dependent enhancement in cell death.
   Creative Biolabs provided the IFN-α receptor (IFNAR) monoclonal antibody Anifrolumab (Cat#: TAB-722) used to block type I IFN signaling in this study. The antibody was crucial in demonstrating that blocking IFNAR reduced the percentage of cell death in SARS-CoV-2-infected MDMs. This blocking assay helped to reveal the role of type I IFNs in mediating the apoptosis of MDMs post-infection, thereby offering insights into the mechanisms of macrophage activation and cell death during SARS-CoV-2 infection.
3. Gong, Ke, et al. "EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer." Nature cancer 1.4 (2020): 394-409. https://doi.org/10.1038/s43018-020-0048-0
   This study explores the impact of EGFR inhibition on type I interferon (IFN) signaling in non-small cell lung cancer (NSCLC). Researchers found that inhibiting EGFR in NSCLC triggers an antiviral defense mechanism, resulting in the upregulation of type I IFNs via the RIG-I-TRIM32-TBK1-IRF3 pathway in EGFR-mutant cells, and via an NF-κB-dependent pathway in EGFR wild-type (EGFRwt) cells. The study demonstrates that the upregulation of type I IFNs contributes to both primary and secondary resistance to EGFR-tyrosine kinase inhibitors (TKIs). Additionally, the study suggests that combining EGFR-TKI treatment with IFN signaling inhibition could improve treatment efficacy and overcome resistance in both EGFR-mutant and EGFRwt NSCLC.
   Creative Biolabs provided the anifrolumab antibody (Cat#: TAB-722) used in this study. Anifrolumab was crucial for experiments involving the inhibition of type I IFN signaling. The use of anifrolumab allowed researchers to demonstrate that blocking IFNAR enhances the sensitivity of NSCLC cells to EGFR inhibition, thereby reducing cell survival and preventing the development of resistance to EGFR-TKIs. This antibody was essential in illustrating the potential therapeutic benefit of combining EGFR-TKIs with IFN signaling inhibitors to improve treatment outcomes in NSCLC.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-722, RRID: AB_3111991)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Anifrolumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Anifrolumab.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "IFNAR"

Select a product category from the dropdown menu below to view related products.